OptimizeRx Corporation
OPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.65 | -0.23 | 0.01 | -24.70 |
| FCF Yield | 5.37% | -3.31% | 3.48% | 0.02% |
| EV / EBITDA | -12.22 | -12.58 | -29.82 | 423.69 |
| Quality | ||||
| ROIC | -9.19% | -10.99% | -9.72% | 0.27% |
| Gross Margin | 64.45% | 59.98% | 62.40% | 58.14% |
| Cash Conversion Ratio | -0.24 | 0.41 | -0.93 | 1.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.84% | 5.28% | 12.97% | 35.57% |
| Free Cash Flow Growth | 158.90% | -177.92% | 4,236.57% | 103.73% |
| Safety | ||||
| Net Debt / EBITDA | -2.23 | -1.08 | 1.91 | -36.26 |
| Interest Coverage | -2.23 | -18.16 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 127.36 | 161.90 | 105.40 | 139.06 |